Clinical Trial Update: A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating a recombinant humanized anti-CD20 monoclonal antibody delivered by subcutaneous injection for primary membranous nephropathy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Recombinant humanized anti-CD20 monoclonal antibody

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Primary Membranous Nephropathy | Phase 1 | Status: RECRUITING